<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000597183"><TermName>cediranib maleate</TermName><TermPronunciation>(seh-DEER-uh-nib MAY-lee-AYT)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. Cediranib maleate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called AZD2171 and Recentin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720983" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;cediranib maleate&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720982" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;maleato de cediranib&quot;" language="es" id="_4"/><SpanishTermName>maleato de cediranib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. El cediranib podría prevenir la formación de vasos sanguíneos nuevos que los tumores necesitan para crecer  y destruir las células cancerosas. Es un tipo de antiangiogénico y un tipo de inhibidor del receptor de la tirosina cinasa del factor de crecimiento endotelial vascular (FCEV). También se llama AZD2171 y Recentin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-05-30</DateFirstPublished><DateLastModified>2009-04-21</DateLastModified></GlossaryTerm>
